Navigation Links
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Date:5/19/2008

ies Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (ii) risks related to achieving positive clinical trial results; (iii) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone in Japan; (iv) the designation of pirfenidone for Fast Track status by the FDA does not guarantee that the FDA will grant Priority Review of the NDA filed by InterMune in connection with the approval of pirfenidone for the treatment of IPF in the United States. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Progress on Pirfenidone in IPF
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Announces Start of Phase 1b Trial of ITMN-191
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...
(Date:12/15/2009)... --A Harvard medical expert internationally recognized as a ... Tour,s decision last month to suspend Doug Barron ... as having the medical condition hypogonadism ... "unreasonable, unfair and discriminatory." ,, Hypogonadism ... levels, often referred to informally as Low ...
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Congressman Fattah Supports Legislation to Address More Funds for Pancreatic Cancer Research 60857 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 1Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 2Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th 14754 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 2
... and NYSE: SNY ) announced today that the ... in favor of the approval of Multaq(R) by the U.S. ... atrial fibrillation (AF). As demonstrated in the ATHENA trial, ... a clinical study a significant reduction in morbidity and mortality ...
... Alternext: ULU) announced that clinical evidence on ... the use of its patented Nanoflex(TM) Technology for Therapeutic ... Meeting in Los Angeles, California March 19-21. The ... on display during the meeting.Clinical evidence will be presented ...
Other Medicine Technology:FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone) 2FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone) 3ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:12/16/2009)... ( http://www.sermo.com ), the world,s largest online community ... new Sermo Vitals Report titled " Diabetes: MD ... physician dialog about diabetes over a one-year period ... of topics, including the therapies physicians discuss most ... on issues related to diabetes. ,, Leveraging ...
(Date:12/16/2009)... access to patient information could improve care, but ... 16 (HealthDay News) -- U.S. physicians support the ... exist about privacy problems, two new studies show. ... practice and specialist doctors in Massachusetts found that ... would improve patient quality of care, 70 percent ...
(Date:12/16/2009)... 14, 2009) Unisense FertiliTech A/S has received a further 1.6 million ... of the EmbryoScope™ Embryo Monitoring System in order to meet the ... invested by LD Pensions and Unisense A/S that continue to own ... ... Denmark (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has received ...
(Date:12/16/2009)... a bachelor degree, an individual can begin working and become ... ... (Vocus) December 16, 2009 -- According to " Measuring ... by the National Center for Public Policy and Higher Education, ... sectors of the economy.”¹ Since 1982, the national price of ...
(Date:12/16/2009)... Hair Shake in all of the Florida Whole Foods store. ... ... Larry Shapiro, hair transplant and hair loss physician , is pleased ... Hair Whey Protein Shake. Dr. Shapiro developed the all natural growth-hormone ... programs, working out and muscle building., , , , ,The Whole Foods ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:Pros and Cons of Electronic Medical Records Weighed 2Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2
... Broad-ranging Report Concludes that Increased Resources Are An Essential ... ... food supply,is at risk, as are the regulatory systems that oversee the ... Board,in a report to be presented today. The subcommittee attributes the,deficiencies to ...
... 4, 2007 In a new evidence-based paper, the ... the United States and 12 other industrialized countries and ... political and social culture of the United States to ... universal health insurance coverage for all Americans. , As ...
... for Quality Long-Term Care Recommendations, WASHINGTON, Dec. ... the National Commission for Quality Long-Term Care,for its ... among policymakers,especially this year,s Presidential candidates. We urge ... the long-term care,challenges our nation faces and to ...
... Corporation,(Nasdaq: HSKA ) today announced it will ... December 6, 2007 at the Grand Hyatt Denver, ... scheduled to begin at 5:05,p.m. Mountain Time., ... Heska Corporation (NASDAQ: HSKA ) sells advanced ...
... Evaluates Best Drugs for 35 Conditions, YONKERS, ... needed between doctors and patients, especially,when it comes ... in the,January issue of Consumer Reports, in which ... initiative about drugs for 35 conditions including,Alzheimer,s disease, ...
... studies show strong link to recreational drugs as well. ... U.S. studies of gay and bisexual men who know ... one-third have recently had unprotected intercourse. , In many ... other HIV-infected men -- a practice called "serosorting," where ...
Other Medicine News:Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 2Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 2Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 3Health News:Internists diagnose health-care system ills, show how to achieve universal coverage 4Health News:NCOA Commends Long Term Care Commission Report 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 2Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 4
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. All ...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... optimum performance with maximum comfort, SheerVision ... medical professionals worldwide. All SheerVision loupes ...
Medicine Products: